Literature DB >> 33073041

Preoperative alpha-fetoprotein (AFP) in hepatocellular carcinoma (HCC): is this 50-year biomarker still up-to-date?

Fabrice Muscari1, Charlotte Maulat1.   

Abstract

Entities:  

Year:  2020        PMID： 33073041      PMCID： PMC7530322          DOI： 10.21037/tgh.2019.12.09

Source DB:  PubMed          Journal:  Transl Gastroenterol Hepatol        ISSN： 2415-1289


× No keyword cloud information.
  25 in total

1.  Is serum alpha-fetoprotein useful for predicting recurrence and mortality specific to hepatocellular carcinoma after hepatectomy? A test based on propensity scores and competing risks analysis.

Authors:  Ju Hyun Shim; Da-Lim Yoon; Seungbong Han; Young-Joo Lee; Sung-Gyu Lee; Kang Mo Kim; Young-Suk Lim; Han Chu Lee; Young-Hwa Chung; Yung Sang Lee
Journal:  Ann Surg Oncol       Date:  2012-05-30       Impact factor: 5.344

2.  Hepatic resection for "BCLC stage A" hepatocellular carcinoma. The prognostic role of alpha-fetoprotein.

Authors:  Roberto Santambrogio; Enrico Opocher; Mara Costa; Matteo Barabino; Massimo Zuin; Emanuela Bertolini; Francesca De Filippi; Savino Bruno
Journal:  Ann Surg Oncol       Date:  2011-07-06       Impact factor: 5.344

3.  The value of the Barcelona Clinic Liver Cancer and alpha-fetoprotein in the prognosis of hepatocellular carcinoma.

Authors:  Rafael Gómez-Rodríguez; Marta Romero-Gutiérrez; Tomás Artaza-Varasa; Concepción González-Frutos; Juan José Ciampi-Dopazo; Gema de-la-Cruz-Pérez; Juan José Sánchez-Ruano
Journal:  Rev Esp Enferm Dig       Date:  2012-06       Impact factor: 2.086

Review 4.  Contribution of alpha-fetoprotein in liver transplantation for hepatocellular carcinoma.

Authors:  Bérénice Charrière; Charlotte Maulat; Bertrand Suc; Fabrice Muscari
Journal:  World J Hepatol       Date:  2016-07-28

5.  Growth rate of asymptomatic hepatocellular carcinoma and its clinical implications.

Authors:  J C Sheu; J L Sung; D S Chen; P M Yang; M Y Lai; C S Lee; H C Hsu; C N Chuang; P C Yang; T H Wang
Journal:  Gastroenterology       Date:  1985-08       Impact factor: 22.682

6.  The resurrection of alphafetoprotein.

Authors:  Morris Sherman
Journal:  J Hepatol       Date:  2010-03-15       Impact factor: 25.083

Review 7.  The growing impact of alpha-fetoprotein in the field of liver transplantation for hepatocellular cancer: time for a revolution.

Authors:  Quirino Lai; Samuele Iesari; Fabio Melandro; Gianluca Mennini; Massimo Rossi; Jan Lerut
Journal:  Transl Gastroenterol Hepatol       Date:  2017-09-16

8.  Significance of alpha-fetoprotein and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma undergoing hepatectomy.

Authors:  Kentaroh Yamamoto; Hiroshi Imamura; Yutaka Matsuyama; Kiyoshi Hasegawa; Yoshifumi Beck; Yasuhiko Sugawara; Masatoshi Makuuchi; Norihiro Kokudo
Journal:  Ann Surg Oncol       Date:  2009-08-11       Impact factor: 5.344

9.  Prognostic value of pretreatment levels of tumor markers for hepatocellular carcinoma on survival after curative treatment of patients with HCC.

Authors:  Hidenori Toyoda; Takashi Kumada; Yuji Kaneoka; Yukio Osaki; Toru Kimura; Akira Arimoto; Hiroko Oka; Osamu Yamazaki; Takao Manabe; Fumihiro Urano; Hobyung Chung; Masatoshi Kudo; Takashi Matsunaga
Journal:  J Hepatol       Date:  2008-05-23       Impact factor: 25.083

10.  Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey.

Authors:  Iwao Ikai; Shigeki Arii; Masamichi Kojiro; Takafumi Ichida; Masatoshi Makuuchi; Yutaka Matsuyama; Yasuni Nakanuma; Kiwamu Okita; Masao Omata; Kenichi Takayasu; Yoshio Yamaoka
Journal:  Cancer       Date:  2004-08-15       Impact factor: 6.860
View more
  4 in total

1.  Correlation of Clinicopathological Profile, Prognostic Factors, and Survival Outcomes with Baseline Alfa-Fetoprotein Levels in Patients With Hepatocellular Carcinoma: A Biomarker that is Bruised but Not Broken.

Authors:  Vaneet Jearth; Prachi S Patil; Shaesta Mehta; Sridhar Sundaram; Vishal Seth; Mahesh Goel; Shraddha Patkar; Munita Bal; Vidya Rao
Journal:  J Clin Exp Hepatol       Date:  2021-11-16

2.  Tribbles pseudokinase 3 (TRIB3) contributes to the progression of hepatocellular carcinoma by activating the mitogen-activated protein kinase pathway.

Authors:  Rui-Qi Wang; Fa-Zhong He; Qian Meng; Wei-Jie Lin; Jia-Mei Dong; Hai-Kui Yang; Yang Yang; Min Zhao; Wen-Tao Qiu; Yong-Jie Xin; Zhi-Ling Zhou
Journal:  Ann Transl Med       Date:  2021-08

3.  The development and validation of a novel senescence-related long-chain non-coding RNA (lncRNA) signature that predicts prognosis and the tumor microenvironment of patients with hepatocellular carcinoma.

Authors:  Enmin Huang; Tao Ma; Junyi Zhou; Ning Ma; Weisheng Yang; Chuangxiong Liu; Zehui Hou; Shuang Chen; Tiago Biachi de Castria; Bing Zeng; Zhen Zong; Taicheng Zhou
Journal:  Ann Transl Med       Date:  2022-07

4.  Identification of the hsa_circ_0039466/miR-96-5p/FOXO1 regulatory network in hepatocellular carcinoma by whole-transcriptome analysis.

Authors:  Feng Yuan; Yongchang Tang; Mingbo Cao; Yupeng Ren; Yuxuan Li; Gaoyuan Yang; Qifeng Ou; Francisco Tustumi; Giovanni Battista Levi Sandri; Driss Raissi; Christine Pocha; Meihai Deng; Zhicheng Yao
Journal:  Ann Transl Med       Date:  2022-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.